Embecta Corp. (EMBC) Q2 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Embecta Corp..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:03.135 Turning to some fiscal second quarter highlights. 00:00:03.135 -- 00:00:08.181 Second quarter revenue totaled $259 million, which exceeded our expectations 00:00:08.181 -- 00:00:11.102 of between $250 and $255 00:00:11.185 -- 00:00:14.950 million that we provided in our last earnings call. 00:00:14.950 -- 00:00:20.196 As compared to the midpoint of our prior guidance range, approximately half of the overachievement 00:00:20.196 -- 00:00:24.662 in the quarter was due to constant currency performance, while the other half was due 00:00:24.662 -- 00:00:29.585 to foreign exchange being less of a headwind than we previously anticipated. 00:00:29.748 -- 00:00:34.494 Turning to some additional highlights, during the second quarter, we published the updated 00:00:34.494 -- 00:00:39.300 FITR Forward Expert Recommendations in Mayo Clinic Proceedings. 00:00:39.300 -- 00:00:43.785 This is an important milestone in our commitment to improving clinical outcomes as the 00:00:43.785 -- 00:00:48.771 recommendations support the best global practices for insulin injection technique, device 00:00:48.771 -- 00:00:51.975 optimization, and provider training. 00:00:51.975 -- 00:00:57.061 Additionally, during Q2, MBECTA conducted a company-wide employee engagement survey through 00:00:57.061 -- 00:01:02.404 Great Place to Work. a global authority on workplace culture, employee experience, 00:01:02.404 -- 00:01:07.190 and the leadership behaviors proven to deliver market-leading revenue, employee retention, 00:01:07.190 -- 00:01:09.233 and increased innovation. 00:01:09.233 -- 00:01:13.359 We had a tremendous response rate from our employees worldwide, and we are pleased to 00:01:13.359 -- 00:01:18.466 announce that we have received certification as a great...